Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.83 |
| ▸ | LMNA | P02545 | 4/20 | 0.83 |
| ▸ | MEN1 | O00255 | 4/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.83 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30762094 | 1.00 | RAB9A (1.00) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL13826736 | 1.00 | RAB9A (1.00) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL28738931 | 1.00 | RAB9A (1.00) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL13906014 | 0.91 | RAB9A (1.00) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL3067021 | 0.91 | RAB9A (1.00) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL13906013 | 0.87 | RAB9A (0.81) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL12746286 | 0.86 | RAB9A (0.76) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL23062734 | 0.86 | RAB9A (0.79) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL10804555 | 0.86 | RAB9A (0.86) | RAB9ANPC1KMT2ALMNAMEN1 | |
| SCHEMBL12746295 | 0.86 | RAB9A (1.00) | RAB9ANPC1KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20240252594-A1 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE LLC (US) | 2024-08-01 | — | — | US | claimed |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE LLC (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023042178-A2 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE, LLC (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2022224118-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE, LLC (US) | 2022-10-27 | — | — | WO | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | disclosed |
| CN-115066424-B | Kv3 modulators | 奥蒂福尼疗法有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240252594-A1 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE LLC (US) | 2024-08-01 | — | — | US | disclosed |
| CN-118267386-A | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-108472288-B | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE LLC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-112703300-B | Apparatus and method for performing a combined power cycle to generate mechanical energy | 哈维尔·卡洛斯·维洛斯·莫埃达诺 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023042178-A2 | COMBINATION THERAPY FOR NEURODEGENERATIVE DISEASES | ALETA NEUROSCIENCE, LLC (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022224118-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | ALETA NEUROSCIENCE, LLC (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058288-A1 | DRUG COCKTAIL FOR TREATMENT OF PARKINSON'S DISEASE, LEWY BODY DISEASE AND MULTIPLE SYSTEM ATROPHY | BAG3, BAG2, PHB1 | RAB9A 572/4885NPC1 1507/4885KMT2A 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.